654.75
+6.59%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bliss GVS Pharma
Its shares trade on NSE under the ticker BLISSGVS.NS. It has been listed since 26 July 2010. In the fiscal year to 31 March 2025, it reported revenue of ₹8.10bn and net income of ₹843.0m. At that date it held total assets of ₹13.01bn and shareholders' equity of ₹10.50bn.
Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2010-07-26. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Jul 2010
- Employees
- 763
- Website
- blissgvs.com ↗
Leadership
Pay as last reported
- Mr. Narsimha KamathChief Executive Officer
- Mr. Deepak SawantChief Financial Officer
- Ms. Aditi BhattCompliance Officer, Company Secretary
- Mr. Gagan SharmaManaging Director, Executive Director, since 2010₹15.0m
- Ms. Shruti RaoWhole-Time Director, since 2021₹6.0m
- Ms. Vibha SharmaWhole-Time Director, since 2022₹6.0m
- Ms. Shilpa BhatiaIndependent Woman Director₹250,000
- Mr. Santosh ParabIndependent Director₹250,000
- Dr. Nandkumar ChodankarAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bliss GVS Pharma Ltd employs 763 full-time staff members in Mumbai.
- The company markets diverse pharma products like capsules, creams, and gels.
- ANOMEX and CONLAX 5/10 are key brands in the portfolio.
Weaknesses
- The company went public on 26 July 2010 via an IPO.
- Headquarters are located in Mumbai, Maharashtra, India.
- Only 763 employees work for the pharmaceutical firm.
Opportunities
- Expansion of other healthcare products includes balm, soap, and shampoo.
- Nasal inhaler and vaginal wash offer additional consumer health segments.
- Petroleum jelly and spray provide diverse topical treatment options.
Threats
- Competition exists for brands like GACET 80/125/170/250/500/1G.
- Market saturation affects products like LOFNAC and MEFINOL significantly.
- Regulatory changes impact effervescent tablets and dry powder for injection.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.